Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.

Eyre, Toby A, Fox, Christopher P, Boden, Ali, Bloor, Adrian, Dungawalla, Moez, Shankara, Paneesha, Went, Richard and Schuh, Anna H (2019) Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. British journal of haematology, 184 (4). pp. 667-671. ISSN 1365-2141. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.

Item Type:	Article
Additional Information:	This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects:	QZ Pathology. Oncology WH Haemic and lymphatic systems. Haematology
Divisions:	Planned IP Care > Oncology and Clinical Haematology
Related URLs:	https://www.ncbi.nlm.nih.gov/pubmed/2946...
Depositing User:	Beth Connors
Date Deposited:	20 Jan 2020 14:06
Last Modified:	20 Jan 2020 14:06
URI:	http://www.repository.uhblibrary.co.uk/id/eprint/2777

Actions (login required)

View Item